Hypersensitivity reactions, including anaphylactic shock, loss of consciousness, collapse, hypotension, dyspnea, and seizure.
Monitor iron toxicity through the periodic evaluation of lab works which monitor the body concentration of iron. Lab monitoring of the following parameters: transferrin saturation, serum ferritin concentrations, hemoglobin, and hematocrit could be helpful to avoid iron overload.
Severe allergic symptoms include: rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); burning or pain at the injection site; burning, numbness, or tingling; chest pain; fainting; loss of consciousness; severe or persistent dizziness, headache, or light-headedness; seizures; shortness of breath; swelling of the hands, ankles, or feet.
Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Moxifloxacin | Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Grepafloxacin | Iron sucrose can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Iron sucrose can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Iron sucrose can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofloxacin | Iron sucrose can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Iron sucrose can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Iron sucrose can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Iron sucrose can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Iron sucrose can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Iron sucrose can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Iron sucrose can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Iron sucrose can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levofloxacin | Iron sucrose can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gemifloxacin | Iron sucrose can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Iron sucrose can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Iron sucrose can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Iron sucrose can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Iron sucrose can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Iron sucrose can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Iron sucrose can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Iron sucrose can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Iron sucrose can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Iron sucrose can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Iron sucrose can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Iron sucrose can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Difloxacin | Iron sucrose can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazufloxacin | Iron sucrose can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prulifloxacin | Iron sucrose can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delafloxacin | Iron sucrose can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sitafloxacin | Iron sucrose can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxolinic acid | Iron sucrose can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rufloxacin | Iron sucrose can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipemidic acid | Iron sucrose can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Iron sucrose. |
| Lymecycline | The serum concentration of Lymecycline can be decreased when it is combined with Iron sucrose. |
| Clomocycline | The serum concentration of Clomocycline can be decreased when it is combined with Iron sucrose. |
| Oxytetracycline | The serum concentration of Oxytetracycline can be decreased when it is combined with Iron sucrose. |
| Demeclocycline | The serum concentration of Demeclocycline can be decreased when it is combined with Iron sucrose. |
| Tetracycline | The serum concentration of Tetracycline can be decreased when it is combined with Iron sucrose. |
| Metacycline | The serum concentration of Metacycline can be decreased when it is combined with Iron sucrose. |
| Minocycline | The serum concentration of Minocycline can be decreased when it is combined with Iron sucrose. |
| Sarecycline | The serum concentration of Sarecycline can be decreased when it is combined with Iron sucrose. |
| Omadacycline | The serum concentration of Omadacycline can be decreased when it is combined with Iron sucrose. |
| Penimepicycline | The serum concentration of Penimepicycline can be decreased when it is combined with Iron sucrose. |
| Levothyroxine | The serum concentration of Levothyroxine can be decreased when it is combined with Iron sucrose. |
| Dimercaprol | Dimercaprol may increase the nephrotoxic activities of Iron sucrose. |
| Cefdinir | Iron sucrose can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferiprone | The serum concentration of Deferiprone can be decreased when it is combined with Iron sucrose. |
| Dolutegravir | Iron sucrose can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Iron sucrose can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levodopa | The bioavailability of Levodopa can be decreased when combined with Iron sucrose. |
| Methyldopa | Iron sucrose can cause a decrease in the absorption of Methyldopa resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Penicillamine | Iron sucrose can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lipoic acid | Iron sucrose can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triethylenetetramine | Triethylenetetramine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pancrelipase | Pancrelipase can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium bicarbonate | Sodium bicarbonate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium carbonate | Calcium carbonate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium acetoacetate | Aluminium acetoacetate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium peroxide | Magnesium peroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Almasilate | Almasilate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium glycinate | Aluminium glycinate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aloglutamol | Aloglutamol can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium silicate | Calcium silicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pantoprazole | Pantoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lansoprazole | Lansoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Esomeprazole | Esomeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rabeprazole | Rabeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexlansoprazole | Dexlansoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexrabeprazole | Dexrabeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium zirconium cyclosilicate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vonoprazan | Vonoprazan can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Olanzapine | Olanzapine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cimetidine | Cimetidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nizatidine | Nizatidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ranitidine | Ranitidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Famotidine | Famotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methantheline | Methantheline can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Promethazine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxepin | Doxepin can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asenapine | Asenapine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metiamide | Metiamide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxatidine acetate | Roxatidine acetate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lafutidine | Lafutidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lavoltidine | Lavoltidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Niperotidine | Niperotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Epinastine | Epinastine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pamidronic acid | Iron sucrose can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zoledronic acid | Iron sucrose can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alendronic acid | Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ibandronate | Iron sucrose can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy. |